Literature DB >> 9679957

AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.

A X Liu1, J R Testa, T C Hamilton, R Jove, S V Nicosia, J Q Cheng.   

Abstract

Three members have been identified in the protein kinase B (PKB) family, i.e., Akt/PKB alpha, AKT2/PKB beta, and AKT3/PKB gamma. Previous studies have demonstrated that only AKT2 is predominantly involved in human malignancies and has oncogenic activity. However, the mechanism of transforming activity of AKT2 is still not well understood. Here, we demonstrate the activation of AKT2 with several growth factors, including epidermal growth factor, insulin-like growth factor 1, insulin-like growth factor II, basic fibroblast growth factor, platelet-derived growth factor, and insulin, in human ovarian epithelial cancer cells. The kinase activity and the phosphorylation of AKT2 were induced by the growth factors and blocked by the phosphatidylinositol (PI) 3-kinase inhibitor, wortmannin, and dominant-negative Ras (N17Ras). Moreover, the activated Ras and v-Src, two proteins that transduce growth factor-generated signals, also activated AKT2, and this activation was not significantly enhanced by growth factor stimulation but was abrogated by wortmannin. These results indicate that AKT2 is a downstream target of PI 3-kinase and that Ras and Src function upstream of PI 3-kinase and mediate the activation of AKT2 by growth factors. The findings also provide further evidence that AKT2, in cooperation with Ras and Src, is important in the development of some human malignancies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679957

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis.

Authors:  Susumu Rokudai; Naoya Fujita; Osamu Kitahara; Yusuke Nakamura; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.

Authors:  K Jiang; D Coppola; N C Crespo; S V Nicosia; A D Hamilton; S M Sebti; J Q Cheng
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome.

Authors:  Brennan T Harmon; Stephanie A Devaney; Heather Gordish-Dressman; Erica K Reeves; Po Zhao; Joseph M Devaney; Eric P Hoffman
Journal:  Hum Genet       Date:  2010-09-26       Impact factor: 4.132

4.  Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition?

Authors:  Selvaraju Veeriah
Journal:  J Chem Biol       Date:  2012-04-26

5.  The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions.

Authors:  Zhigang Yuan; Alejandro Villagra; Lirong Peng; Domenico Coppola; Michele Glozak; Eduardo M Sotomayor; Jiandong Chen; William S Lane; Edward Seto
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

6.  PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

Authors:  Jean L Nakamura; Amelia Karlsson; Nils D Arvold; Alexander R Gottschalk; Russell O Pieper; David Stokoe; Daphne A Haas-Kogan
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

7.  Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo.

Authors:  Isaac Marin-Valencia; Chendong Yang; Tomoyuki Mashimo; Steve Cho; Hyeonman Baek; Xiao-Li Yang; Kartik N Rajagopalan; Melissa Maddie; Vamsidhara Vemireddy; Zhenze Zhao; Ling Cai; Levi Good; Benjamin P Tu; Kimmo J Hatanpaa; Bruce E Mickey; José M Matés; Juan M Pascual; Elizabeth A Maher; Craig R Malloy; Ralph J Deberardinis; Robert M Bachoo
Journal:  Cell Metab       Date:  2012-06-06       Impact factor: 27.287

8.  The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia.

Authors:  J-N Gong; J Yu; H-S Lin; X-H Zhang; X-L Yin; Z Xiao; F Wang; X-S Wang; R Su; C Shen; H-L Zhao; Y-N Ma; J-W Zhang
Journal:  Cell Death Differ       Date:  2013-09-27       Impact factor: 15.828

9.  Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.

Authors:  Maria U Rømer; Lise Larsen; Hanne Offenberg; Nils Brünner; Ulrik A Lademann
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

10.  Role of Src signal transduction pathways in scatter factor-mediated cellular protection.

Authors:  Saijun Fan; Qinghui Meng; John J Laterra; Eliot M Rosen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.